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Barack Obama’s historic inauguration
was greeted with great anticipation by
stem cell researchers. Once he took his
place in the Oval Office, they believed,
he would produce the key to their scien-
tific shackles.
For stem cell researchers, it’s been
a long eight years. On August 9, 2001,
President Bush prohibited federal funding
for research on human embryonic stem
cell lines (hESCs) created after August 9,
2001. Obama, during his campaign,
repeatedly promised to lift the ban, even
stating during the Science Debate that
he would reverse the policy via Executive
Order.
‘‘As somebody who’s a stem cell
research advocate and has been in
a wheelchair now for 24 years, I am thrilled
about the prospect of President Obama
lifting the Bush restrictions as he takes
office,’’ says Danny Heumann of the
Christopher and Dana Reeve Foundation.
‘‘Whatever federal monies that we can get
for this research I think will pay huge divi-
dends in making sure that we get ethical,
moral research done in this country, and
get cures and treatments from the labs
to patients’ bedsides.’’
‘‘We have had this great engine of
scientific progress, the NIH, basically on
the sidelines of stem cell research.
There’s much work to be done to make
up for this,’’ says Bernard Siegel, execu-
tive director of the Genetics Policy Insti-
tute, a stem cell stakeholders umbrella
organization that promotes research
advocacy initiatives.
In the years since President Bush’s
funding ban, the stem cell research
community has learned to get by largely
on its own. For one thing, a rich variety
of organizations have emerged to fill the
funding vacuum. States such as Wiscon-
sin and California and patient advocacy
groups now form a patchwork of granting
institutions that have supplied the funds
keeping U.S. stem cell programs alive.
Meanwhile, to ensure a complete work
separation between the so-called presi-
dential cell lines and those derived more
recently, scientists have learned to buy
duplicates of all of lab equipment or set
up second labs, and universities have
established parallel accounting systems.
Exactly how the Obama Administration
might alter the hESC research landscape
remains unknown. Though the antici-
pated blessing of the White House
appears to signal a new era, many pitfalls
lie ahead, with legal, financial, and other
hurdles lurking along the way.
Scientists themselves are uniformly
enthusiastic about the anticipated policy
shift. ‘‘The whole world sees this as
a very important movement for freeing
up opportunities for U.S. researchers to
have an impact in this area,’’ says Alan
Trounson, head of the California Institute
for Regenerative Medicine.
‘‘We could avoid duplication and work
together in a concerted way to enable
whatever opportunities exist to be eval-
uated much sooner than previously
possible,’’ Trounson adds.
Allowing federal funding to support
research on more lines would clear up
many fundamental research questions,
says Story Landis, Director of the National
Institute for Neurological Disorders and
Stroke and Chair of the NIH Task Force
on Stem Cells. With more and more
researchers reporting new ways to induce
pluripotent cells from adult tissues, ‘‘is it
still important to be using hESC? The
answer is we simply don’t know. Expand-
ing the ability of NIH to fund stem cell
research would allow those comparisons
to be done in a much more straightfor-
ward and expeditious fashion.’’
Researcher Derek Hei expects any Ob-
ama policy shift to speed progress toward
clinical trials. As the technical director of
the National Stem Cell Bank, which is
charged with characterizing and distrib-
uting the 21 so-called presidential registry
lines exempt from the federal ban, Hei is
acutely aware of these cells’ shortcom-
ings. One of the biggest problems sur-
rounding these lines is their suitability for
clinical trials. Most were derived using
mouse feeder cells and might be contam-
inated with murine retroviruses. If trans-
planted into patients during clinical trials,
they carry the risk of introducing new
pathogens into humans.
‘‘Since then, we have made significant
progress in understanding how to culture
new stem cell lines without feeder cells.
And I would much rather distribute lines
that we know could go into clinical trials
and not have human transplantation
issues,’’ Hei says.
Others await the creation of federal
rules and procedures to clear up confu-
sion surrounding the ethical derivation of
new embryonic stem cell lines. ‘‘Right
now, every granting entity has its own
rules and regulations regarding stem cell
research ethics. So we’re forced to look
into the provenance of every single cell
line,’’ says Bernard Siegel. Any new
federal rules would likely be adopted
across granting agencies by default.
Meanwhile, stem cell organizations
funded by the states are unlikely to
change course in a new funding land-
scape. ‘‘I don’t think we’ll see states that
have already funded stem cell research
institutes cut back. But it could be that
more states would be hesitant to start
these organizations now,’’ Siegel says.
Having a central source of funding is
also expected to staunch the brain drain
from states lacking such funding organi-
zations.
Yet the time when those federal funds
can finally be released might be further
off than scientists believe. On inaugura-
tion day, Obama’s transition team had
no comment on when he might act to
lift the ban, only that it would not occur
in the first few days after he takes office.
The delay may signal a more nuanced
approach to what experts say is complex
legal territory.
If President Obama attempts to issue
an executive order reversing the funding
ban, warns Louis Guenin, a lecturer at
Harvard University Law School and an
expert on stem cell law, he will run into
the legislative equivalent of a brick wall.
That obstacle is known as the Dickey-
Wicker Amendment, a piece of legislation
that forbids the use of federal funds to
support research ‘‘in which human
embryos are created, destroyed, dis-
carded, or knowingly be subjected to
risk of injury or death greater than allowed
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Profilefor research on fetuses in utero.’’ It was
passed in 1996 and has been almost
automatically renewed by Congress every
year since.
‘‘The permission granted from an
Executive Order is not broad enough.
NIH would lose the lawsuit. The only
reason for this stroke of the pen action
is grandstanding by Obama,’’ Guenin
says.
Not only does Dickey-Wicker pose
a practical barrier to federal funding, but
it is also inconsistent with any federally
supported hESC research policy. ‘‘To
fund studies of new stem cell lines but
not the derivation of those lines is an arti-
ficial line. Because once you support
investment in studying these lines, you’re
indirectly supporting the destruction of
embryos,’’ Guenin says.
The only route around the wall, accord-
ing to Guenin, is for Congress to pass
legislation overriding Dickey-Wicker. The
so-called DeGette bill, which permits
research on hESC lines derived from
surplus embryos created for reproductive
uses, has already been introduced on
Capitol Hill. If the bill comes up for
a vote, reckons Cynthia Cohen of the Ken-
nedy Institute of Ethics at Georgetown
University, the relatively liberal current
Congress is likely to pass it. However,
the DeGette bill could still be challenged
in court on the basis of Dickey-Wicker. If
that came to pass, Congress would get
an opportunity to repeal the amendment.
If and when the Obama Administration
overcomes these legal hurdles, it’s an
open question as to how many federal
dollars might be available to flow toward
hESC research. The country is mired in
the deepest recession in recent memory,
and the NIH budget has essentially been
flat or falling in terms of real dollars for
several years.
Despite these potential setbacks, hope
for a more nurturing environment for
hESC research is in the air. ‘‘The future
is extremely bright for the entire field of
regenerative medicine,’’ Siegel says.
‘‘It’ll be a powerful new force unleashed.’’
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